Why Advocate for FDA Funding?
Current treatment for Parkinson’s is based on a 50-year-old therapy, which treats only some symptoms for some people and eventually loses its effectiveness. There’s no treatment available to stop or slow the progression of the disease. The Parkinson’s community is depending on the FDA to swiftly approve safe and effective new therapies that will help people with Parkinson’s live happier and healthier lives.
That is why PAN supports robust funding for this agency and actively supports efforts to streamline the approval process and increase the agency’s access to scientific and medical experts, and works to ensure that patients have a voice in the decision making regarding drugs and devices that impact them.
PAN is a member of the Alliance for a Stronger FDA , a coalition of more than 185 nonprofit and industry groups working to increase annual appropriations for the FDA. The FDA is funded through a combination of Congressional appropriations and fees paid by drug and device sponsors, as regulated by Congress.
Current Funding Efforts
Fiscal Year 2013 Funding
On March 26, 2013 President Obama signed a funding bill to keep all government programs funded through September 2013. The FDA received a slight funding increase.
Fiscal Year 2014 Funding
PAN is advocating for $2.6 billion for the FDA so that it can uphold its critical mission, which impacts each and every American. For more information, see this one-page summary .
In June, both the House and Senate Appropriations Committees approved their respective versions of the Agriculture appropriations bill that provides funding for the FDA.
It is unclear when the House and Senate will hold full chamber votes on their respective measures.
User fees are paid by companies when they file a new drug or device application with the Agency and have contributed to the advancement of new therapies and medical devices. Unfortunately, FDA user fees have been subject to sequestration, meaning that approximately $85 million in private funding has been lost in the current fiscal year. Both the House and Senate Appropriations Committees included language in their bills that supports excluding FDA user fees from sequestration.
FDA Safety Over Sequestration Act
On July 18, Reps. Eshoo (D-CA), Lance (R-NJ), Matsui (D-CA), and Rogers (R-MI) introduced the FDA Safety Over Sequestration Act (H.R. 2725), which would exempt FDA user fees from sequestration starting in FY 2014 and beyond.
PAN sent a letter  in support of the legislation on July 25, noting that user fees are a key source of private funding that directly supports the advancement of new and innovative therapies and devices.
FDA User Fee Protection Act
On July 31, Sens. Pryor (D-AR), Blunt (R-MO), Coats (R-IN), Franken (D-MN), and Moran (R-KS) introduced the FDA User Fee Protection Act (S. 1413), legislation similar to the measure introduced in House that would exempt FDA user fees from sequestration starting FY 2014 and beyond.
PAN sent a letter  in support of the legislation on August 7.